Stereotaxis, Inc. Reports Improved First Quarter 2012 Financial Results

Published: May 08, 2012

ST. LOUIS, May 8, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) today reported financial results for the first quarter ended March 31, 2012.

Management Comments
Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis, said, "In the first quarter, we continued to capitalize on strong market response to the release of the Epoch Solution and robust utilization, realizing a 20% improvement in revenue over the prior year quarter. By quarter end, we had completed 25 upgrades to the Niobe® ES system in existing sites since its launch in December 2011; on pace with our forecast to achieve 40 upgraded sites during the first half of 2012. We expect Niobe® ES system sales will gain momentum throughout the year as we increase reference sites and optimize product value."

"We also improved operating loss by $4.6 million, or 52%, over last year through a combination of top line growth and significantly lower operating spend, which declined 21% year over year," continued Kaminski.

"In order to accelerate our timeline to achieve breakeven, we are executing a plan to reduce operating costs by an additional 15% to 20% without compromising our revenue growth strategies. With the Epoch Solution product development behind us, we can focus research dollars on enhancements that ensure market adoption and long-term success of the robotic platform. In addition, we have opportunity for greater efficiencies within our capital sales organization through alignment with our local clinical organization.

"These strategies, which are built on the successful commercial launch and improving revenue of the Niobe® ES system, position us to reach breakeven while continuing to refine our technology, expand our offering through the Vdrive product and leverage our strategic partners in global market opportunities," concluded Kaminski.

Financial Results
Revenue for the first quarter 2012 totaled $12.3 million, a 20% increase over the prior year quarterly revenue of $10.2 million and a 6% increase over fourth quarter 2011 revenue of $11.6 million. The Company realized revenue of $2.8 million in Niobe® ES system sales and $2.0 million in Odyssey system sales in the first quarter 2012. Recurring revenue in the quarter improved 20% from the year-ago quarter to $7.1 million.

The Company generated global new capital orders of $3.0 million in the first quarter, comprised of ten Niobe® ES system upgrades, two Vdrive robotic navigation systems and $2.1 million in orders related to the Odyssey system. This compares to $7.1 million in global new capital orders in the first quarter 2011 and $3.6 million in the fourth quarter. Ending capital backlog for the first quarter was $16.9 million.

Gross margin in the quarter was $8.5 million, or 69.4% of revenue, versus $7.2 million, or 70.6% of revenue, in the first quarter 2011 and $8.3 million, or 71.4%, in the fourth quarter.

Operating expenses were $12.7 million in the first quarter, down $3.3 million from the year ago period and down $0.2 million sequentially. The decline was primarily attributed to headcount and discretionary spending cuts in the second half of 2011.

Operating loss in the quarter was $(4.2) million, compared to $(8.8) million in the prior year quarter, a 52% improvement and down $0.4 million sequentially, a 9% improvement.

The net loss for the first quarter was $(5.8) million, or $(0.11) per share, compared to a net loss of $(9.5) million, or $(0.17) per share, reported for the first quarter 2011 and $(5.5) million, or $(0.10) per share, in the fourth quarter 2011. The weighted average shares outstanding for the first quarter of 2012 totaled 55.0 million, compared with 54.7 million in the first quarter 2011 and 54.9 million in the fourth quarter.

Cash burn for the first quarter 2012 was $4.3 million, compared to $11.0 million in the prior year quarter and $14.8 million in the 2011 fourth quarter. The decrease from the prior year quarter is principally due to a smaller net loss and lower working capital while the decline from the 2011 fourth quarter is primarily due to lower working capital and the Company's final repayment of the Biosense Webster advance.

At March 31, 2012, Stereotaxis had cash and cash equivalents of $10.5 million, compared to $14.0 million at December 31, 2011. At quarter end, total debt was $39.5 million, including $14.8 million related to Cowen Healthcare Royalty Partners financing.

"In line with our commitment to capitalize the company, we have entered into definitive agreements to raise approximately $18.5 million in two financing transactions with new and existing institutional investors," stated Kaminski.

The financing consists of $10 million the Company will raise in a private offering of common stock and $8.5 million of unsecured, subordinated convertible promissory debentures, which will be convertible into shares of common stock at all times following the date the Company is required to receive shareholder approval of the transactions. The closing of the transactions is subject to standard and customary closing conditions. Net proceeds from these financings will be used to repay $7 million of the revolving credit facility guaranteed by Alafi Capital and Sanderling Venture Partners, for working capital and general corporate purposes. The Company expects to amend its credit agreement with Silicon Valley Bank to extend its revolving credit facility, which will decrease from $20 million to $13 million after pay down of $7 million of the guaranteed portion, to March 31, 2013, upon closing of the transaction.

Cost Reduction
The Company has announced immediate plans to further lower its cost structure throughout the organization with reductions that do not directly impact top line growth. As a result, it expects to reduce operating spend by an additional 15-20% from first quarter levels by the 2012 fourth quarter.

2012 Milestones
Stereotaxis reaffirmed the following milestones for 2012:

  • Complete additional capital raise and secure extended credit agreement with Silicon Valley Bank
  • Achieve at least 10 new Niobe® ES system sales
  • Complete 40 Niobe® ES system upgrades during the first half of 2012

Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, May 8, 2012 at 8:30 a.m. Eastern Time, to discuss first quarter results and operational progress. The dial-in number for the conference call is 1-877-941-1465 for domestic participants and 1-480-629-9772 for international participants. Participants are asked to call the above numbers 5-10 minutes prior to the start time. A real-time, listen-only webcast of the conference call will be accessible at in the Investors section under Event Calendar. Listeners should go to the website at least 15 minutes prior to the live conference call to install any necessary audio software.

An audio replay of the call will be available for seven days following the call and can be accessed by dialing 1-800-406-7325 for domestic callers and 1-303-590-3030 for international callers, both using passcode 4536824. The call also will be available for 90 days at

About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey portfolio of lab optimization, networking and patient information management systems and the Vdrive Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop circular catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit and

Back to news